O12. Survival of patients with advanced EGFR-mutated NSCLC treated with EGFR TKIS in routine clinical practice

BACKGROUND: The use of epidermal growth factor receptor (EGFR) TKIs in EGFR-mutated non-small cell lung cancer (NSCLC) moved the survival boundary for these patients up to impressive 19 to 35 months, as reported in seven randomized clinical trials (RCTs). In addition, latest results of RCTs show sig...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Transl Lung Cancer Res
Main Authors: Hitij, Nina Turnsek, Sadikov, Aleksander, Knez, Lea, Mohorcic, Katja, Jakelj, Andraz, Cufer, Tanja
Formáid: Artigo
Teanga:Inglês
Foilsithe: Pioneer Bioscience Publishing Company 2014
Ábhair:
CELCC 2014 Abstracts
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367788/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB011
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla